Literature DB >> 17318900

Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells.

Yi Guo1, Xiaolin Zi, Zach Koontz, Alison Kim, Jun Xie, Richard Gorlick, Randall F Holcombe, Bang H Hoang.   

Abstract

We previously reported the Wnt receptor low-density lipoprotein receptor-related protein 5 (LRP5) was frequently expressed in osteosarcoma (OS) tissue and correlated with metastasis and a lower disease-free survival. Subsequent in vitro analysis revealed that dominant-negative, soluble LRP5 (sLRP5) can reduce in vitro cellular invasion. In the current study, we examined the molecular mechanisms of blocking canonical Wnt signaling by sLRP5 in Saos-2 osteosarcoma cells. Transfection of sLRP5 caused a marked up-regulation of E-cadherin in this cell line. This increase in E-cadherin, seen primarily at the cell-cell contact borders, was associated with down-regulation of Slug and Twist, transcriptional repressors which mediate cancer invasion and metastasis. In contrast, N-cadherin, a mesenchymal marker, was reduced by sLRP5. In addition, blocking Wnt signaling by sLRP5 modulated other epithelial and mesenchymal markers (keratin 8 and 18, fibronectin), suggesting a reversal of epithelial-mesenchymal transition (EMT) seen during cancer progression. SLRP5 also reduced the expression of matrix metalloproteinase (MMP) 2 and 14, consistent with a decrease in invasive capacity. SLRP5 transfection decreased both Met expression and hepatocyte growth factor (HGF)-induced cell motility. Taken together, these results support a role for Wnt/LRP5 signaling in invasiveness of a subset of OS cells. Copyright (c) 2007 Orthopaedic Research Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318900     DOI: 10.1002/jor.20356

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  50 in total

1.  Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

Authors:  Thanh H Dellinger; Kestutis Planutis; Danielle D Jandial; Ramez N Eskander; Micaela E Martinez; Xiaolin Zi; Bradley J Monk; Randall F Holcombe
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

Review 2.  Osteoanabolic and dual action drugs.

Authors:  Gaia Tabacco; John P Bilezikian
Journal:  Br J Clin Pharmacol       Date:  2019-04-03       Impact factor: 4.335

3.  Slug gene expression supports human osteoblast maturation.

Authors:  Elisabetta Lambertini; Gina Lisignoli; Elena Torreggiani; Cristina Manferdini; Elena Gabusi; Tiziana Franceschetti; Letizia Penolazzi; Roberto Gambari; Andrea Facchini; Roberta Piva
Journal:  Cell Mol Life Sci       Date:  2009-09-11       Impact factor: 9.261

4.  Influence of β-catenin small interfering RNA on human osteosarcoma cells.

Authors:  Fan Zhang; Anmin Chen; Jianfeng Chen; Tian Yu; Fengjing Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

5.  TIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway.

Authors:  Ruhui Li; Jianguo Liu; Hong Wu; Lidi Liu; Lijun Wang; Shaokun Zhang
Journal:  Mol Cell Biochem       Date:  2014-04-27       Impact factor: 3.396

6.  Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling.

Authors:  Yi Guo; Jun Xie; Elyssa Rubin; Ya-Xiong Tang; Fritz Lin; Xiaolin Zi; Bang H Hoang
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model.

Authors:  Yi Guo; Elyssa M Rubin; Jun Xie; Xiaolin Zi; Bang H Hoang
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

Review 8.  Gene translocations in musculoskeletal neoplasms.

Authors:  Balaji Krishnan; Gaurav Khanna; Denis Clohisy
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

Review 9.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

10.  SLUG: a new target of lymphoid enhancer factor-1 in human osteoblasts.

Authors:  Elisabetta Lambertini; Tiziana Franceschetti; Elena Torreggiani; Letizia Penolazzi; Antonio Pastore; Stefano Pelucchi; Roberto Gambari; Roberta Piva
Journal:  BMC Mol Biol       Date:  2010-02-03       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.